Molecular biology and genetics/Biologie et génétique moléculaires

Age-related changes of metallothionein 1/2 and metallothionein 3 expression in rat brain

Rosaria Scudiero *, Luisa Cigliano, Mariailaria Verderame

Department of Biology, University of Naples Federico II, via Mezzocannone 8, 80134 Napoli, Italy

A R T I C L E   I N F O

A B S T R A C T

Neurodegeneration is one of the main physiological consequences of aging on brain. Metallothioneins (MTs), low molecular weight, cysteine-rich proteins that bind heavy-metal ions and oxygen-free radicals, are commonly expressed in various tissues of mammals. MTs are involved in the regulation of cell proliferation and protection, and may be engaged in aging. Expression of the ubiquitous MTs (1 and 2) and the brain specific MT3 have been studied in many neurodegenerative disorders. The research results indicate that MTs may play important, although not yet fully known, roles in brain diseases; in addition, data lack the ability to identify the MT isoforms functionally involved. The aim of this study was to analyse the level of gene expression of selected MT isoforms during brain aging. By using real-time PCR analysis, we determined the MT1/2 and MT3 expression profiles in cerebral cortex and hippocampus of adolescent (2 months), adult (4 and 8 months), and middle-aged (16 months) rats. We show that the relative abundance of all types of MT transcripts changes during aging in both hippocampus and cortex; the first effect is a generalized decrease in the content of MTs transcripts from 2- to 8-months-old rats. After passing middle age, at 16 months, we observe a huge increase in MT3 transcripts in both cortical and hippocampal areas, while the MT1/2 mRNA content increases slightly, returning to the levels measured in adolescent rats. These findings demonstrate an age-related expression of the *MT3* gene. A possible link between the increasing amount of MT3 in brain aging and its different metal-binding behaviour is discussed.

© 2016 Académie des sciences. Published by Elsevier Masson SAS. All rights reserved.

1. Introduction

Metallothioneins (MTs) are small, intracellular heavy-metal-binding proteins involved in metal detoxification and protection against oxidative stress [1,2]. Ubiquitously present in living organisms [3,4], the mammalian MT family falls into four subgroups: MT1, MT2, MT3, and MT4 [5]. MT1 and MT2 encode through a series of gene duplication events for multiple isoforms present in almost all tissues, while MT3 and MT4 evolved in a single form to accomplish specific roles in brain and epithelium, respectively [6–8]. In the mammalian brain, MT1 and MT2 are preferentially expressed in astrocytes and activated microglia [9]; MT3 is expressed predominantly in neurons and, to a lesser extent, in astrocytes [10].

It has been demonstrated that MT1 and MT2 protect the central nervous system (CNS) in response to experimentally induced injury [11] and following viral infections [12], whereas MT3 neither affects inflammatory responses nor plays an important antioxidant role [11]. Indeed, the MT3 functional role and regulation in CNS is still a matter of debate [10,13]. MT3 is known as a growth inhibitory factor

* Corresponding author.
  E-mail address: rosaria.scudiero@unina.it (R. Scudiero).

able to inhibit the survival and neurite formation in cultured neurons in vitro [14]. MT3 mRNA and protein are upregulated following brain injury [15] and downregulated in Alzheimer's disease (AD) [14,16].

The known functions of MTs include metalloregulatory roles in cell growth and differentiation [17], so it is not surprising that most mammalian tissues contain age-related basal levels of MTs, with the major amount found in developing cells [18]. Enhanced synthesis of MTs is also observed in rapidly proliferating tissues, stressing their crucial role in normal and neoplastic cell growth [18–20]. However, the MTs' role in aging is controversial: in mammals, MT expression has been found to increase in aged kidney [21], whereas decreased significantly with aging in the skin [22].

Aging is a major risk factor for brain neurodegenerative disorders, including cerebrovascular disease, AD, Parkinson's disease (PD) and cancer [23–26]. Brain aging is accompanied with molecular, functional and genetic changes, leading to increased susceptibility to diseases and cognitive impairments. As it has been proven in the mouse, MTs downregulation results in a progressive neurodegeneration, leading to early aging, morbidity, and mortality [27]; the neurodegenerative alterations are attenuated by MTs overexpression, suggesting the neuroprotective role of MTs in aging [27]. These studies, however, did not include the identification of the MT isoforms functionally involved.

In this study, by using real-time PCR analysis, we examined and compared the expression of MT1/2 and MT3 genes during aging in the rat brain. In particular, we evaluated the MT1/2 and MT3 expression profiles in the cerebral cortex and hippocampus of pubertal (2 months), adult (4 and 8 months), and middle-aged (16 months) rats.

Our results demonstrate an age-related expression of the MT3 gene, thus, suggesting its implication in physiological changes associated with aging.

2. Materials and methods

2.1. Animal and experimental design

Male Wistar rats (Charles River, Calco, Como, Italy) of 2 months of age (adolescent), with the same starting body weight (160 ± 10 g), were individually caged in a temperature-controlled room ($23 \pm 1\,°C$) submitted to a 12-h light/12-h dark cycle. Animals were housed in the Animal Care Facility at the Department of Biology, with ad libitum access to water and to a standard diet (Mucedola 4RF21; Settimo Milanese, Milan, Italy) up to 4 (social maturity, group 1), 8 (adulthood, group 2), or 16 (aged, group 3) months. Eight animals of each group were anesthetized with chloral hydrate (40 mg/100 g body wt) and killed by decapitation. Group 4 was comprised 8 adolescent rats sacrificed four days after their arrival in the animal facility. The brains were quickly removed and the cerebral cortex and hippocampus were dissected on ice. Samples of each brain region were snap frozen in liquid nitrogen immediately and stored at $-80\,°C$ for subsequent RNA isolation. The livers of the rats belonging to group 4 were also collected, frozen and stored at $-80\,°C$ for

RNA isolation. The protocols for animal care and use were approved by the Scientific Ethics Committee on Animal Experimentation of the University Federico II of Naples. All experimental animal procedures were carried out in compliance with the national guidelines for the care and use of research animals (D.L.116/92, implementation of EEC directive 609/86). All efforts were made to minimize animal suffering and to reduce the number of animals used.

2.2. RNA purification and cDNA synthesis

Total RNA was extracted according to the TRI-Reagent (Sigma–Aldrich) protocol. The quality of each total RNA was checked by electrophoresis on 2% agarose gel stained with ethidium bromide and by measuring the optical density at 260/280 nm. A ratio of 1.8–2.0 was accepted for further reverse transcription. The QuantiTect Reverse Transcription Kit (Qiagen) was used for the removal of genomic DNA contamination and for the subsequent cDNA synthesis. Approximately 1 μg of total RNA was used, according to the kit's protocol.

2.3. Quantitative real-time PCR analysis

The real-time PCR reactions were carried out in quadruplicate in an Applied Biosystems 7500 Real-Time System by using the Power SYBR Green Master Mix PCR (Applied Biosystems) following procedures recommended by the manufacturer. Each SYBR Green reaction (total volume: 20 μL) contained 12 μL of real-time PCR Master Mix, 1 μL of each of the forward and reverse primers (10 μM), 2 μL of 1:1 diluted cDNA, and 4 μL of nuclease-free water. Nuclease-free water for the replacement of the cDNA template was used as a negative control. For the internal standard control, the expression of β-actin gene was quantified. Primer sequences were designed using Primer Express software (Applied Biosystems). A single pair of specific primers for both MT1 and MT2 isoforms was designed on the nucleotide sequences of Rattus norvegicus MT1 (NM 138826.4) and MT2 (NM 001137564.1). Specific primers for MT3 were designed on the R. norvegicus template NM 053968.3, choosing the most divergent sequence tracts rather than MT1/2 isoforms. β-actin primers were designed on the exon junction 75/76 (forward primer) on R. norvegicus template NM031144.2. All the primers used in real-time PCR analysis are listed in Table 1. PCR was performed under the following conditions: holding stage of 95 °C per 10 min; cycling stage (45 cycles): 95 °C × 10 s – 60 °C × 10 s – 72 °C × 10 s; melting stage: 95 °C × 5 s – 65 °C × 1 min – 95 °C × 30 s – 40 °C × 30 s. The melting curve analysis of PCR products was performed in

Table 1
Specific primers used for semiquantitative real-time PCR analyses.

Name	Nucleotide sequence (5′–3′)	Length	Direction
MT1/2_F	ATGGACCCCAACTGCTCCTG	20-mer	Sense
MT1/2_R	CTTTGCAGACACAGCCCTGGG	21-mer	Antisense
MT3_F	CCCCTGTCCTACTGGTGGT	19-mer	Sense
MT3_R	CTGCATTTCTCGGCCTTG	18-mer	Antisense
β-act_F	ACCCGCCACCAGTTCGCCAT	20-mer	Sense
β-act_R	CGGCCCACGATGGAGGGGAA	20-mer	Antisense

order to ensure gene-specific amplification. Changes in the gene expression relative to the different samples were calculated according to the standard $2^{-\Delta\Delta Ct}$ method described by Livak and Schmittgen [28].

2.4. Statistical analysis

Data are presented as mean ± standard error of the mean (SEM) from four separate experiments in each sample. Statistical analyses were carried out by StatView software (Altura Software, Inc.). The differences between the mean values were analysed by one-way analysis of variance (ANOVA) followed by Fisher's LSD test. The differences were considered significant when $P < 0.05$.

3. Results

3.1. Expression of MT isoforms in liver and brains of adolescent rats

As a preliminary step, we firstly decided to compare the relative abundance of MT1/2 and MT3 transcripts in the liver, the cerebral cortex, and the hippocampus of adolescent rats. As expected, MT1 and MT2 are the major forms in the liver, whereas MT3 is the most represented isoform (Fig. 1) in the two areas of the brain, with the level of the cortex higher than that of the hippocampus. However, a significant amount of MT3 transcripts was also detectable in the liver, as well as lower levels of MT1/MT2 isoforms were found both in the cortical and hippocampal areas (Fig. 1).

3.2. Expression of MT isoforms in the aging brain

Once the MTs gene expression profile in adolescent (2-month-old) rats established, we carried out the study evaluating MT1/2 and MT3 mRNAs levels in the


Fig. 1. Real-time PCR analysis of metallothionein isoforms expression in liver, cerebral cortex and hippocampus of 2-month-old rats. MT1/2 and MT3 mRNA levels are shown relative to β-actin mRNA. The data represent the mean ± SEM (eight rats per group).

hippocampus and the cortex of adult (4- and 8-month-old), and middle-aged (16-month-old) rats. Real-time PCR revealed a huge increase in MT3 expression in both regions of the brain, in aged rats. In particular, the level of this transcript increased by 16 times compared to the 2-month-old rats in the cerebral cortex (Fig. 2a) and by about 14 times in the hippocampus (Fig. 2b). Interestingly, we did not observe a linear increase in MT3 transcripts with the age from 2 to 8 months in both the hippocampus and the cortex; on the contrary, a slight but significant decrease in MT3 transcripts was observed in adult rats when compared with young rats (Fig. 2).

As regarding MT1/2 expression in brain areas, real-time PCR analysis demonstrated that the amount of these transcripts decreased in adults (4- and 8-month-old rats), and increased slightly only in aged rats (16 months),


Fig. 2. Effect of aging on MT3 gene expression in rat cortical (a) and hippocampal (b) areas. The MT3 mRNA expression was normalized to that of β-actin mRNA and converted in fold change, compared with 2-month-old rats. The data represent the mean ± SEM (eight rats per group). Significance of differences is shown. $^*P < 0.05$; $^{**}P < 0.001$. ^{a}Significance vs. 2 months; ^{aa}Significance vs. 4 and 8 months.

Fig. 3. Effect of aging on *MT1* and *MT2* genes expression in rat cortical (a) and hippocampal (b) areas. The MT1/2 mRNAs expression was normalized to that of β-actin mRNA and converted in fold change, compared with the 2-month-old rats. The data represent the mean ± SEM (eight rats per group). The significance of differences is shown. $^*P < 0.05$; [a]Significance vs. 2 months; [aa]Significance vs. 4 and 8 months.

reaching more or less the level measured in 2-months rats, both in cortical (Fig. 3a) and hippocampal (Fig. 3b) areas.

4. Discussion

Aging is a dominant risk factor for many CNS disorders, among which AD and PD [23,24,26,29]. Aging contributes to the physiological decline of cells and tissues; in the brain, it is associated with inflammation, increased oxidative damage, protein aggregate accumulation and demyelination, whereas it gives rise to a modest neuron and synapse loss [30,31]. Age-related changes in CNS gene expression levels have been reported and many genes, and relative proteins, have been suggested as prognostic biomarkers of neurodegenerative disorders [32–34]. Recently, MT genes have been introduced in the list of early biomarkers of neuronal disorders [27,29]. It has been demonstrated that MTs overexpression in mouse brain provide neuroprotection against deleterious consequences of oxidative and nitrosative stress. However, the authors did not identify the MT isoform(s) responsive to neurodegeneration [27]. Therefore, a major aim of this study was to show whether changes in MT isoforms ratio occur with aging in rats' hippocampus and cerebral cortex.

MT3 is reported as the most abundant isoform expressed in the brain, and our data are consistent with this result. Here, we also show that the relative abundance of all types of MT transcripts change during aging in both hippocampus and cortex; surprisingly, the first effect is a generalized decrease in the content of MTs transcripts from 2-month-old to 8-month-old rats. This pattern can be explained according to two hypotheses. In the first one, it is possible to assume that the rate of MT expression measured in adolescent rats is strictly linked to the physiological state of the brain, consisting of active, proliferating cells with a high metabolic rate. On the other

hand, it cannot be excluded that the higher content of MTs detected in adolescent rats compared with adults is due to the stress that these animals undergo in their early stages of life. Indeed, once in the animal facility, the rats are maintained in individual cages under optimum conditions of humidity, temperature, photoperiod, with water ad libitum and right amount of food; these conditions would lead to a decrease in MTs expression, lacking the stressful factors that may cause their temporary increase.

After passing middle age, at 16 months, we observe a huge increase in MT3 transcripts in both cortical and hippocampal areas, while the MT1/2 mRNA content increases slightly, returning to the levels measured in young rats (2 months). These findings demonstrate an age-related expression of the *MT3* gene, whereas the lower levels of *MT1/2* genes might suggest a marginal role of these players, if any, in the aging process of the brain. Structural and functional studies on MT3 demonstrated the stronger Cu-thionein character of MT3 compared to that of MT1 and MT2 [35,36], corroborating the hypothesized role of this MT isoform in the brain as a key element in the homeostasis and metabolism of copper ions in the CNS [36]. Recently, Fu et al. have ascertained an age-dependent increase in the Cu levels in rat brains [37].

Therefore, it is conceivable that the increasing amount of MT3 expression in the aging brain might be linked to its different metal-binding behaviour with respect to the other MT isoforms and to its specific neuronal growth inhibitory bioactivity. Together, these features could better meet the needs of aged brain cells.

Disclosure of interest

The authors declare that they have no competing interest.

References

[1] S. Takahashi, Positive and negative regulators of the metallothionein gene (review), Mol. Med. Rep. 12 (2015) 795–799.

[2] X.B. Ling, H.W. Wei, J. Wang, Y.Q. Kong, Y.Y. Wu, J.L. Guo, T.F. Li, J.K. Li, Mammalian metallothionein-2A and oxidative stress, Int. J. Mol. Sci. 17 (2016) 1483.

[3] D.H. Hamer, Metallothionein, Annu. Rev. Biochem. 55 (1986) 913–951.

[4] G. Isani, E. Carpenè, Metallothioneins, unconventional proteins from unconventional animals: a long journey from nematodes to mammals, Biomolecules 4 (2014) 435–457.

[5] A.T. Miles, G.M. Hawksworth, J.H. Beattie, V. Rodilla, Induction, regulation, degradation, and biological significance of mammalian metallothioneins, Crit. Rev. Biochem. Mol. Biol. 35 (2000) 35–70.

[6] A. Moleirinho, J. Carneiro, R. Matthiesen, R.M. Silva, A. Amorim, L. Azevedo, Gains, losses and changes of function after gene duplication: study of the metallothionein family, PLoS One 6 (2011) e18487.

[7] R.D. Palmiter, S.D. Findley, T.E. Whitmore, D.M. Durnam, MT-III, a brain-specific member of the metallothionein gene family, Proc. Natl. Acad. Sci. U S A 89 (1992) 6333–6337.

[8] C.J. Quaife, S.D. Findley, J.C. Erickson, G.J. Froelick, E.J. Kelly, B.P. Zambrowicz, R.D. Palmiter, Induction of a new metallothionein isoform (MT-IV) occurs during differentiation of stratified squamous epithelia, Biochemistry 33 (1994) 7250–7259.

[9] M.Ø. Pedersen, R. Jensen, D.S. Pedersen, A.D. Skjolding, C. Hempel, L. Maretty, M. Penkowa, Metallothionein-I + II in neuroprotection, Biofactors 35 (2009) 315–325.

[10] S.J. Lee, J.Y. Koh, Roles of zinc and metallothionein-3 in oxidative stress-induced lysosomal dysfunction, cell death, and autophagy in neurons and astrocytes, Mol. Brain 3 (2010) 30.

[11] M. Giralt, M. Penkowa, N. Lago, A. Molinero, J. Hidalgo, Metallothionein-1 + 2 protect the CNS after a focal brain injury, Exp. Neurol. 173 (2002) 114–128.

[12] B.L. Williams, K. Yaddanapudi, C.M. Kirk, A. Soman, M. Hornig, W.I. Lipkin, Metallothioneins and zinc dysregulation contribute to neurodevelopmental damage in a model of perinatal viral infection, Brain Pathol. 16 (2006) 1–14.

[13] A.K. West, J. Hidalgo, D. Eddins, E.D. Levin, M. Aschner, Metallothionein in the central nervous system: roles in protection, regeneration and cognition, Neurotoxicology 29 (2008) 488–502.

[14] Y. Uchida, K. Takio, K. Titani, Y. Ihara, M. Tomonaga, The growth inhibitory factor that is deficient in the Alzheimer's disease brain is a 68 amino acid metallothionein-like protein, Neuron 7 (1991) 337–347.

[15] I. Hozumi, T. Inuzuka, S. Tsuji, Brain injury and growth inhibitory factor (GIF) – a mini review, Neurochem. Res. 23 (1998) 319–328.

[16] V. Colangelo, J. Schurr, M.J. Ball, R.P. Pelaez, N.G. Bazan, W.J. Lukiw, Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling, J. Neurosci. Res. 70 (2002) 462–473.

[17] M.G. Cherian, M.D. Apostolova, Nuclear localization of metallothionein during cell proliferation and differentiation, Cell Mol. Biol. (Noisy-le-Grand) 46 (2000) 347–356.

[18] N. Thirumoorthy, K.T. Manisenthil Kumar, A. Shyam Sundar, L. Panayappan, M. Chatterjee, Metallothionein: an overview, World J. Gastroenterol. 13 (2007) 993–996.

[19] D. Lim, K.M. Jocelyn, G.W. Yip, B.H. Bay, Silencing the metallothionein-2A gene inhibits cell cycle progression from G1- to S-phase involving ATM and cdc25A signaling in breast cancer cells, Cancer Lett. 276 (2009) 109–117.

[20] R. Mehrian-Shai, M. Yalon, A.J. Simon, E. Eyal, T. Pismenyuk, I. Moshe, S. Constantini, A. Toren, High metallothionein predicts poor survival in glioblastoma multiform, BMC Med. Genomics 8 (2015) 68.

[21] J. Leierer, M. Rudnicki, S.J. Braniff, P. Perco, C. Koppelstaetter, I. Mühlberger, S. Eder, J. Kerschbaum, C. Schwarzer, A. Schroll, G. Weiss, S. Schneeberger, S. Wagner, A. Königsrainer, G.A. Böhmig, G. Mayer, Metallothioneins and renal ageing, Nephrol. Dial. Transplant. 31 (2016) 1444–1452.

[22] C. Ma, L.F. Li, X. Chen, Expression of metallothionein-I and II in skin ageing and its association with skin proliferation, Br. J. Dermatol. 164 (2011) 479–482.

[23] T. Niccoli, L. Partridge, Ageing as a risk factor for disease, Curr. Biol. 22 (2012) R741–R752.

[24] R.A. Harris, L. Tindale, R.C. Cumming, Age-dependent metabolic dysregulation in cancer and Alzheimer's disease, Biogerontology 15 (2014) 559–577.

[25] D.K. Smith, M. He, C.L. Zhang, J.C. Zheng, The therapeutic potential of cell identity reprogramming for the treatment of aging-related neurodegenerative disorders, Prog. Neurobiol. (2016) 30067–30068 (S0301-0082).

[26] C. Rodríguez-Nogales, E. Garbayo, M.M. Carmona-Abellán, M.R. Luquin, M.J. Blanco-Prieto, Brain aging and Parkinson's disease: new therapeutic approaches using drug delivery systems, Maturitas 84 (2016) 25–31.

[27] S. Sharma, M. Ebadi, Significance of metallothioneins in aging brain, Neurochem. Int. 65 (2014) 40–48.

[28] K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)), Methods 25 (2001) 402–408.

[29] S. Sharma, C.S. Moon, A. Khogali, A. Haidous, A. Chabenne, C. Ojo, M. Jelebinkov, Y. Kurdi, M. Ebadi, Biomarkers in Parkinson's disease (recent update), Neurochem. Int. 63 (2013) 201–229.

[30] G. Bartzokis, T.A. Tishler, P.H. Lu, P. Villablanca, L.L. Altshuler, M. Carter, D. Huang, N. Edwards, J. Mintz, Brain ferritin iron may influence age- and gender-related risks of neurodegeneration, Neurobiol. Aging 28 (2007) 414–423.

[31] P.H. Lu, G.J. Lee, E.P. Raven, K. Tingus, T. Khoo, P.M. Thompson, G. Bartzokis, Age-related slowing in cognitive processing speed is associated with myelin integrity in a very healthy elderly sample, J. Clin. Exp. Neuropsychol. 33 (2011) 1059–1068.

[32] S.D. Ginsberg, Expression profile analysis of brain aging, in: D.R. Riddle (Ed.), SourceBrain Aging: Models, Methods, and Mechanisms, CRC Press/Taylor & Francis,, Boca Raton, FL, USA, 2007 (chapter 7).

[33] M.S. Spagnuolo, B. Maresca, M.P. Mollica, G. Cavaliere, C. Cefaliello, G. Trinchese, M.G. Esposito, R. Scudiero, M. Crispino, P. Abrescia, L. Cigliano, Haptoglobin increases with age in rat hippocampus and modulates Apolipoprotein E mediated cholesterol trafficking in neuroblastoma cell lines, Front Cell Neurosci. 8 (2014) 212.

[34] A. Elobeid, S. Libard, M. Leino, S.N. Popova, I. Alafuzoff, Altered proteins in the aging brain, J. Neuropathol. Exp. Neurol. 75 (2016) 316–325.

[35] S. Toriumi, T. Saito, T. Hosokawa, Y. Takahashi, T. Numata, M. Kurasaki, Metal binding ability of metallothionein-3 expressed in *Escherichia coli*, Basic Clin. Pharmacol. Toxicol. 96 (2005) 295–301.

[36] E. Artells, O. Palacios, M. Capdevila, S. Atrian, In vivo-folded metal-metallothionein 3 complexes reveal the Cu-thionein rather than Zn-thionein character of this brain-specific mammalian metallothionein, FEBS J. 281 (2014) 1659–1678.

[37] S. Fu, W. Jiang, W. Zheng, Age-dependent increase of brain copper levels and expressions of copper regulatory proteins in the subventricular zone and choroid plexus, Front Mol. Neurosci. 8 (2015) 22.